Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00302458
Status:
COMPLETED
Last Update Posted:
2016-02-29
First Post:
2006-03-13
Brief Title:
A Study of Repeat Dosing of OROS Methylphenidate Hydrochloride CONCERTA and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Crossover Study of Repeat Dosing of OROS Methylphenidate Hydrochloride CONCERTA and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double-blind randomized placebo-controlled five-period crossover study to examine the likability of a repeated administration of immediate release methylphenidate hydrochloride IR-MPH 40 mg and OROS-MPH CONCERTA 72 mg in healthy adults Hypotheses are as follows
Hypothesis 1 the subjective feelings of detection and likeability will be greater for periods of IR-MPH administration than after OROS-MPH administration irregardless of sequence
Hypothesis 2 the greater ratings of feelings of detection and likeability will be associated with the periods of most rapid change in plasma d-MPH and not with the magnitude of plasma d-MPH concentration other than the OROS-MPH to IR-MPH condition in which they coincide and
Hypothesis 3 the subjective feelings of dislike will be greatest for the two conditions in which IR-MPH is the second condition
Hypothesis 1 the subjective feelings of detection and likeability will be greater for periods of IR-MPH administration than after OROS-MPH administration irregardless of sequence
Hypothesis 2 the greater ratings of feelings of detection and likeability will be associated with the periods of most rapid change in plasma d-MPH and not with the magnitude of plasma d-MPH concentration other than the OROS-MPH to IR-MPH condition in which they coincide and
Hypothesis 3 the subjective feelings of dislike will be greatest for the two conditions in which IR-MPH is the second condition
Detailed Description:
The main goal of this study is to assess whether the abuse liability potential of delayed repeated administrations of different formulations of MPH is moderated by the oral delivery system in which a delivery system with slower onset may be safer than one with more rapid early release To this end the investigators will compare repeated administration of orally administered therapeutic doses of a short IR-MPH and a long-acting formulation of MPH OROS-MPH in the following areas
1 pharmacokinetic profile of MPH assessing rate of onset of MPH action indexed through change in plasma level and
2 abuse liability indexed through detection and likeability
The investigators will test all combinations of initial administration and then delayed repeated administration of the two formulations IR-MPH to IR-MPH IR-MPH to OROS-MPH OROS-MPH to IR-MPH OROS-MPH to OROS-MPH and placebo to placebo
1 pharmacokinetic profile of MPH assessing rate of onset of MPH action indexed through change in plasma level and
2 abuse liability indexed through detection and likeability
The investigators will test all combinations of initial administration and then delayed repeated administration of the two formulations IR-MPH to IR-MPH IR-MPH to OROS-MPH OROS-MPH to IR-MPH OROS-MPH to OROS-MPH and placebo to placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None